61 related articles for article (PubMed ID: 11522023)
1. Release of soluble urokinase receptor from vascular cells.
Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator urokinase receptor as a diagnostic and prognostic biomarker in type 2 diabetic patients with cardiovascular disease.
Mohammed MS; Ahmed HS
J Cardiovasc Thorac Res; 2023; 15(3):154-160. PubMed ID: 38028718
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock.
Hongisto M; Lassus J; Tarvasmäki T; Sans-Roselló J; Tolppanen H; Kataja A; Jäntti T; Sabell T; Banaszewski M; Silva-Cardoso J; Parissis J; Jurkko R; Spinar J; Castrén M; Mebazaa A; Masip J; Harjola VP;
Eur Heart J Acute Cardiovasc Care; 2022 Aug; 11(10):731-8. PubMed ID: 35949144
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke.
Różański D; Szlufik S; Tomasiuk R; Milanowski Ł; Figura M; Saramak K; Myrcha P; Koziorowski D
Brain Sci; 2021 Dec; 12(1):. PubMed ID: 35053782
[TBL] [Abstract][Full Text] [Related]
5. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
Rasmussen LJH; Petersen JEV; Eugen-Olsen J
Front Immunol; 2021; 12():780641. PubMed ID: 34925360
[TBL] [Abstract][Full Text] [Related]
6. Role of Inflammation in Coronary Epicardial and Microvascular Dysfunction.
Godo S; Takahashi J; Yasuda S; Shimokawa H
Eur Cardiol; 2021 Feb; 16():e13. PubMed ID: 33897839
[TBL] [Abstract][Full Text] [Related]
7. Coagulation and Fibrinolysis in Obstructive Sleep Apnoea.
Bikov A; Meszaros M; Schwarz EI
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799528
[TBL] [Abstract][Full Text] [Related]
8. Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea.
Bocskei RM; Meszaros M; Tarnoki AD; Tarnoki DL; Kunos L; Lazar Z; Bikov A
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32075014
[No Abstract] [Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.
Huang Y; Zhou H; Wu Y; Yang Y; Li W; Lu J; Hu Y
Dis Markers; 2017; 2017():4719403. PubMed ID: 29109596
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
11. Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in Patients With Major Depressive Disorder.
Gustafsson A; Ventorp F; Wisén AG; Ohlsson L; Ljunggren L; Westrin Å
Biomark Insights; 2017; 12():1177271917704193. PubMed ID: 28469403
[TBL] [Abstract][Full Text] [Related]
12. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
[TBL] [Abstract][Full Text] [Related]
13. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
Erkut N; Menteşe A; Özbaş HM; Ermantaş N; Sümer A; Örem A; Sönmez M
Turk J Haematol; 2016 Jun; 33(2):135-40. PubMed ID: 26376588
[TBL] [Abstract][Full Text] [Related]
15. Principles in the design of ligand-targeted cancer therapeutics and imaging agents.
Srinivasarao M; Galliford CV; Low PS
Nat Rev Drug Discov; 2015 Mar; 14(3):203-19. PubMed ID: 25698644
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase-type plasminogen activator receptor: a useful biomarker for coronary artery disease and clinical outcomes?
Harskamp RE; Roe MT
J Am Heart Assoc; 2014 Oct; 3(5):e001431. PubMed ID: 25341888
[No Abstract] [Full Text] [Related]
17. Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.
Gozdzik W; Adamik B; Gozdzik A; Rachwalik M; Kustrzycki W; Kübler A
PLoS One; 2014; 9(6):e98923. PubMed ID: 24911522
[TBL] [Abstract][Full Text] [Related]
18. Induction of brain microvascular endothelial cell urokinase expression by Cryptococcus neoformans facilitates blood-brain barrier invasion.
Stie J; Fox D
PLoS One; 2012; 7(11):e49402. PubMed ID: 23145170
[TBL] [Abstract][Full Text] [Related]
19. Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression.
Yang J; Duh EJ; Caldwell RB; Behzadian MA
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3273-80. PubMed ID: 20089873
[TBL] [Abstract][Full Text] [Related]
20. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).
Pliyev BK
Mol Cell Biochem; 2009 Jan; 321(1-2):111-22. PubMed ID: 18830568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
